Deals
The pact between Madrigal Pharmaceuticals and Ruzhou Ribo Life Sciences could complement the former’s Rezdiffra, the first FDA-approved therapy for MASH. That drug made $287.3 million in the third quarter of 2025.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Syneos Health announced on Wednesday that it has agreed to acquire Synteract, a full-service Contract Research Organization (CRO) focused on the biopharmaceutical industry.
Novartis acquired Vedere Bio in a deal totaling up to $280 million. The takeout broadens Novartis’ footprint in gene and cell therapy, with Vedere Bio’s gene therapy platforms for ophthalmic disorders.
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
The deal, which is worth up to $2.15 billion, is expected to close in the first quarter of 2021 and is subject to regulatory approval.
Bayer is paying $2 billion upfront for AskBio’s AAV-based gene therapy pipeline of treatments for Pompe disease, among others, and could pay an additional $2 billion in potential milestones.
Foghorn Therapeutics hits the Nasdaq offering 7.5 million shares at $16 apiece.
Bay Area-based insitro snapped up neighboring Haystack Sciences to bolster its machine-learning drug discovery programs with that company’s higher resolution dataset-producing technology.
OT-58 is Orphan’s novel investigational enzyme replacement therapy. It is currently in Phase I/II development for classical HCU, a rare metabolic disorder marked by increased levels of plasma homocysteine.
Arixa Pharmaceuticals announced on Thursday that Pfizer’s hospital business has agreed to acquire the company. Arixa has been developing oral antibiotics for antibiotic-resistant Gram-negative infections.
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.